The CPHI Pharma Awards 2025 took place 28 October at Messe Frankfurt, Germany to celebrate the forefront of innovation, excellence, and collaboration in the pharmaceutical industry. These prestigious awards honor pioneers driving advancements in drug development, revolutionizing manufacturing processes, championing sustainability, and shaping the future of pharma worldwide.
CordenPharma was proud to be shortlisted as a finalist in two categories at the CPHI Awards 2025 – API Development & Innovation and CEO of the Year – both of which recognize our innovative technology and leadership in combining deep scientific expertise with a commitment to improving patient outcomes.
Dr. Mimoun Ayoub, Global Head of Peptides & Oligonucleotides Platforms, accepts the CPHI Pharma Award for API Development & Innovation on 28 October in Frankfurt, DE.
We’re incredibly proud of our Innovation Team – (from left to right) Dr. Tim Kramer, Dr. Fabian Hogenkamp, Dr. Stefan Peters, Dr. Mareike Helmdach, Dr. Mimoun Ayoub and Dr. Andreas Hans Heindl – for their groundbreaking work on Tag-Assisted Peptide Synthesis (TAPS) – a next-generation technology revolutionizing peptide manufacturing to meet the growing demand for scalable and sustainable peptide outsourcing.
The CordenPharma Team accepts the API Development & innovation Award on 28 October in Frankfurt – (from left to right) Dr. Andreas Hans Heindl, Dr. Mareike Helmdach, Dr. Stefan Peters, Dr. Mimoun Ayoub, Dr. Fabian Hogenkamp, and Dr. Tim Kramer – for their groundbreaking work on Tag-Assisted Peptide Synthesis (TAPS).
We are proud to win the API Development & Innovation Award for our Tag-Assisted Peptide Synthesis (TAPS), a next-generation technology revolutionizing peptide manufacturing to meet the growing demand for scalable and sustainable peptide outsourcing.
Indeed, the global peptide therapeutics market is expanding rapidly, driven by biologically active peptides like GLP-1 analogues. However, current manufacturing technologies, particularly SPPS, are resource-intensive, environmentally burdensome, and limited in worldwide production capacity.
TAPS solves this by combining the control of SPPS with the scalability of LPPS, eliminating resin use, reducing solvent consumption by over 90% and substantially reducing the amount of raw materials used. The peptide remains in the organic phase via a patented TAG-anchor molecule while impurities and excess amino-acid derivatives or reagents are extracted into the aqueous phase. This allows for continuous solution-phase synthesis with simple aqueous workups. The organic phase is then carried over for the next coupling and cleavage cycle.
(CordenPharma Photo) Preparation of peptide synthesis using TAPS technology at CordenPharma Liestal (CH).
Compared to SPPS, TAPS improves efficiency, sustainability, and scale. It eliminates resin handling, drastically cuts solvent use, and simplifies purification. Unlike LPPS, TAPS retains precise stepwise control, allowing full compatibility with SPPS reagents and know-how.
TAPS provides a greener, more economical alternative that integrates into existing small-molecule assets, enabling broad application without investment in peptide-specific hardware.
This innovation opens the door for automation, modular synthesis (fragment approaches), and green manufacturing practices. It directly supports pharmaceutical trends toward flexible, scalable production of complex, high-value APIs under increasing regulatory scrutiny.
TAPS is not just a lab-scale improvement – it’s an industrial innovation ready for GMP rollout, with clear benefits for pharma innovators.
Get in touch with our team of experts to explore bespoke end-to-end CDMO support of your complete drug lifecycle
at any scale.